Share

Profile & Fundamentals

Recursion Pharmaceuticals Profile & Fundamentals

Name: Recursion Pharmaceuticals financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Company profile record

Recursion Pharmaceuticals Inc

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset: Recursion Pharmaceuticals Inc
Security type: Common Stock
Sector: Health Care
Industry: Biotechnology
HQ: 🇺🇸 United States
Head office: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101

Leadership & scale

Chief executive: Dr. Najat Khan Ph.D.
CEO year born: 1984
Full-time employees: 600
Fiscal year end: December
IPO date: 2021-04-16

Fundamentals snapshot

Updated 2026-09-16

Market Cap: USD 2.0B
P/E: --
Revenue (Q2 26): USD 7.7M
Profit (Q2 26): USD -131.0M
Dividend Yield: --
Revenue (FY 25): USD 74.7M
Shares in public float: 518.5M
Insider ownership: 2.27%

Reporting & identifiers

Symbol: RXRX.NASDAQ
Listing: 🇺🇸 United States | Dividend Tax: 30%
Ticker Currency: USD
Income Statement Currency: USD
Balance Sheet Currency: USD
Cash Flow Currency: USD
EPS Currency: USD
Contract Type: SPOT
ISIN: US75629V1044
Asset ID: equity_24b377f3-f43f-576b-9216-ff7e3e56e9eb

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Top holders

BlackRock Inc43,192,306 shares · 8.05% · Reported 2026-03-31
ARK Investment Management LLC40,212,769 shares · 7.50% · Reported 2026-03-31
State Street Corp28,490,638 shares · 5.31% · Reported 2026-03-31
Baillie Gifford & Co Limited.23,487,907 shares · 4.38% · Reported 2026-06-30
State Street® SPDR® S&P® Biotech ETF23,296,341 shares · 4.34% · Reported 2026-08-31
Vanguard Portfolio Management, LLC22,759,100 shares · 4.24% · Reported 2026-03-31
Vanguard Capital Management, LLC22,244,387 shares · 4.15% · Reported 2026-03-31

View more holders (8)

ARK Disruptive Innovation Full Composite20,667,375 shares · 3.85% · Reported 2026-06-30
ARK Innovation ETF19,503,944 shares · 3.64% · Reported 2026-08-31
Scottish Mortgage Ord18,174,384 shares · 3.39% · Reported 2026-07-31
Vanguard MStar Total Stk Mkt Idx Invest15,939,942 shares · 2.97% · Reported 2026-07-31
ARK Genomic Revolution ETF14,450,107 shares · 2.69% · Reported 2026-08-31
SoftBank Group Corp13,636,515 shares · 2.54% · Reported 2026-06-30
ARK Genomic Revolution13,476,095 shares · 2.51% · Reported 2026-06-30
iShares Russell 2000 ETF12,937,625 shares · 2.41% · Reported 2026-08-31

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

Recursion's financial performance highlights the erratic reality of an early-stage drug developer that has not yet commercialized a medicine. For the twelve months ending June 30, 2026, revenue stood at $54.9 million against an operating deficit of $544 million. Because the company depends on sporadic milestone payments from partners rather than steady product sales, revenue plunged nearly 60% year-over-year in the second quarter of 2026 after earlier project phases wrapped up. However, reported losses are beginning to narrow as management enforces strict spending discipline. Operating expenses fell considerably in recent quarters, reflecting post-merger streamlining and lower data purchase costs. Even with these savings, cash generation remains negative, meaning incoming partner payments cushion spending rather than achieving self-sufficiency.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

The published data is insufficient to draw this chart.

Profitability & Margins

AI Review

Profitability margins remain deeply negative, reflecting an R&D-heavy business where laboratory running costs vastly exceed early partnership payments. In fiscal 2025, gross margin registered at negative 62%, while operating margins remained below negative 300% due to ongoing laboratory overhead and clinical trial expenses. These severe deficits are a natural feature of pre-commercial biotechnology rather than a temporary slump. High-throughput automated screening carries significant fixed costs that cannot be scaled down easily when milestone payments pause. Lasting profit margins will only appear once internally owned drug candidates secure regulatory approval or yield substantial commercial sales royalties.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-17.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2019-12-31	1,711,000	-60,952,000	-62,525,000	-2,577.32	-3,649.39	-3,654.3	-3,562.36
2020-12-31	3,413,000	-52,134,000	-87,006,000	100	-2,479.2	-2,549.25	-1,527.51
2021-12-31	10,000,000	-198,412,000	-178,074,000	100	-1,827.75	-1,780.74	-1,984.12
2022-12-31	39,681,000	-120,883,000	-239,421,000	-21.66	-619.26	-603.36	-304.64
2023-12-31	43,876,000	-300,332,000	-328,066,000	2.94	-797.84	-747.71	-684.5
2024-12-31	58,839,000	-372,869,000	-463,661,000	23.12	-814.09	-788.02	-633.71
2025-12-31	74,681,000	-378,277,000	-644,759,000	-61.96	-867.87	-863.35	-506.52

Shares outstanding — chart values
Reporting date	Shares outstanding
2019-01-01	22,000,000
2020-01-01	167,056,100
2021-01-01	169,369,000
2022-01-01	185,669,700
2023-01-01	233,158,200
2024-01-01	336,036,000
2025-01-01	526,719,700
2026-01-01	532,460,100

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions
Company Events
- Dated insider transactions
- Material company activity

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.